India Seeks 60-Day Probe Into Denial Of Drug Sales To Retail Chains
This article was originally published in PharmAsia News
Executive Summary
An Indian government agency has begun a preliminary investigation into whether some drug makers are refusing to sell directly to large corporate retail chains. The Monopolies and Restrictive Trade Practices Commission requested the Director General Of Investigation and Registration look into the allegations and report back in 60 days. Allegedly responsible are drug wholesalers and drug makers Lupin, Maneeah Pharma and Sandoz, said to have discusses selling only to the group's members. (Click here for more
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.